Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$126.24

-0.38 (-0.30%)

14:18
11/06/18
11/06
14:18
11/06/18
14:18

Sage Therapeutics pricing for Zulresso at a premium to Piper Jaffray estimate

Piper Jaffray analyst Danielle Brill, who maintained an Overweight rating and $206 price target on Sage Therapeutics shares, noted that the announced plans to price Zulresso at $25,000-$35,000 per course -- should it be approved on its December 19 PDUFA date -- which is at a premium to Piper's estimated net pricing of $15,000. Brill also noted that the drug's sales force has been hired, which includes ~130 reps, and ~50 patient support/access personnel, and she is awaiting final commercial details following PDUFA announcement.

  • 06

    Nov

  • 06

    Nov

  • 27

    Nov

  • 19

    Dec

SAGE Sage Therapeutics
$126.24

-0.38 (-0.30%)

11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.

TODAY'S FREE FLY STORIES

RF

Regions Financial

$15.78

-0.345 (-2.14%)

13:10
11/20/18
11/20
13:10
11/20/18
13:10
Options
Bullish short-term option play in Regions Financial »

Bullish short-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ECA

Encana

$7.14

-0.47 (-6.18%)

13:05
11/20/18
11/20
13:05
11/20/18
13:05
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
11/20/18
11/20
13:00
11/20/18
13:00
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

SPY

SPDR S&P 500 ETF Trust

$265.59

-3.69 (-1.37%)

, SPX

S&P 500

$0.00

(0.00%)

12:59
11/20/18
11/20
12:59
11/20/18
12:59
General news
Trump says Saudi Arabia remains 'steadfast partner,' may never know all facts »

In a statement that…

SPY

SPDR S&P 500 ETF Trust

$265.59

-3.69 (-1.37%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$41.82

-0.23 (-0.55%)

12:55
11/20/18
11/20
12:55
11/20/18
12:55
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TJX

TJX

$47.05

-1.92 (-3.92%)

12:52
11/20/18
11/20
12:52
11/20/18
12:52
Recommendations
TJX analyst commentary  »

TJX labor, transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADI

Analog Devices

$89.07

3.52 (4.11%)

12:50
11/20/18
11/20
12:50
11/20/18
12:50
Upgrade
Analog Devices rating change  »

Analog Devices upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

, MSFT

Microsoft

$102.65

-1.97 (-1.88%)

12:48
11/20/18
11/20
12:48
11/20/18
12:48
OnTheFly
Game On: Nintendo, Microsoft still committed to E3 as Sony plans to skip »

Welcome to "Game On," The…

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

MSFT

Microsoft

$102.65

-1.97 (-1.88%)

SNE

Sony

$49.86

-1.12 (-2.20%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$49.80

0.63 (1.28%)

T

AT&T

$29.79

-0.55 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

12:40
11/20/18
11/20
12:40
11/20/18
12:40
Options
Bearish spread in Invesco Senior Loan Portfolio as shares set 52-week lows »

Bearish spread in Invesco…

12:40
11/20/18
11/20
12:40
11/20/18
12:40
General news
Treasury Action: yields are mixed along the curve »

Treasury Action: yields…

NOK

Nokia

$5.58

-0.145 (-2.53%)

12:35
11/20/18
11/20
12:35
11/20/18
12:35
Options
Nokia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$125.44

-0.82 (-0.65%)

12:27
11/20/18
11/20
12:27
11/20/18
12:27
Hot Stocks
Motorola Solutions wins second patent infringement suit against Hytera Mobilfunk »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

CLF

Cleveland-Cliffs

$9.37

-0.6 (-6.02%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Options
Cleveland-Cliffs call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMAC

MMA Capital

$26.50

-0.2 (-0.75%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
MMA Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SANW

S&W Seed

$3.05

(0.00%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
S&W Seed to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

TGT

Target

$69.29

-7.84 (-10.16%)

, BBY

Best Buy

$64.05

1.86 (2.99%)

12:19
11/20/18
11/20
12:19
11/20/18
12:19
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in negative…

TGT

Target

$69.29

-7.84 (-10.16%)

BBY

Best Buy

$64.05

1.86 (2.99%)

CPB

Campbell Soup

$40.60

2.13 (5.54%)

KLIC

Kulicke & Soffa

$22.18

2.28 (11.46%)

A

Agilent

$67.54

4.97 (7.94%)

LIVN

LivaNova

$102.03

-18.25 (-15.17%)

LB

L Brands

$30.14

-4.39 (-12.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 27

    Nov

  • 05

    Dec

  • 11

    Dec

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.